Showing results (441-450 of 554) with videos related to
Sort By:
Pageof 56
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Innovations and challenges in melanoma: summary statement from the first Cambridge conferenceMichael B Atkins, David E Elder, Richard Essner, et al.European Urology Oncology|July 10, 2021
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 TrialBrian I Rini, Michael B Atkins, Elizabeth R Plimack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryKrishna S Gunturu, Kenneth R Meehan, Todd A Mackenzie, et al.European Urology|July 14, 2020
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical TrialBrian I Rini, Robert J Motzer, Thomas Powles, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinomaT K Choueiri, A P Fay, K P Gray, et al.Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 24, 2022
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trialsAjay K Singh, Finnian R McCausland, Brian L Claggett, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 StudyMichael B Atkins, F Stephen Hodi, John A Thompson, et al.The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.JAMA Oncology|December 23, 2021
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas Powles, Michael B Atkins, et al.Pageof 56